Landec Corporation
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of hyaluronate acid (HA) in bulk form, as well as formulated and filled syringes, cartridges, and vials for injectable products used in treating a range of medical conditions and procedures. Its prod… Read more
Landec Corporation (LDE) - Net Assets
Latest net assets as of August 2025: €-10.54 Million EUR
Based on the latest financial reports, Landec Corporation (LDE) has net assets worth €-10.54 Million EUR as of August 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€235.20 Million) and total liabilities (€245.74 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-10.54 Million |
| % of Total Assets | -4.48% |
| Annual Growth Rate | -36.71% |
| 5-Year Change | -99.34% |
| 10-Year Change | -99.37% |
| Growth Volatility | 39.32 |
Landec Corporation - Net Assets Trend (2014–2025)
This chart illustrates how Landec Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Landec Corporation (2014–2025)
The table below shows the annual net assets of Landec Corporation from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-05-31 | €1.34 Million | -88.19% |
| 2024-05-31 | €11.31 Million | +714.28% |
| 2023-05-31 | €-1.84 Million | -101.70% |
| 2022-05-31 | €108.14 Million | -46.67% |
| 2021-05-31 | €202.78 Million | -12.23% |
| 2020-05-31 | €231.04 Million | -14.47% |
| 2019-05-31 | €270.14 Million | +6.96% |
| 2018-05-31 | €252.56 Million | +10.70% |
| 2017-05-31 | €228.15 Million | +7.44% |
| 2016-05-31 | €212.35 Million | -3.53% |
| 2015-05-31 | €220.11 Million | +7.50% |
| 2014-05-31 | €204.76 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Landec Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 386.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (May 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €206.58 Million | 15462.28% |
| Total Equity | €1.34 Million | 100.00% |
Landec Corporation Competitors by Market Cap
The table below lists competitors of Landec Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BOS L ZY 10
F:967
|
$75.14 Million |
|
Polymetals Resources Ltd
AU:POL
|
$75.17 Million |
|
Kewaunee Scientific Corporation
NASDAQ:KEQU
|
$75.20 Million |
|
Global Lighting Technologies Inc
TW:4935
|
$75.22 Million |
|
KLARABO SVERIGE AB
F:F5H
|
$75.13 Million |
|
Abion Inc.
KQ:203400
|
$75.09 Million |
|
Lanna Resources Public Company Limited
BK:LANNA
|
$75.08 Million |
|
Richmond International Travel & Tours Co Ltd
TWO:2743
|
$75.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Landec Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 11,315,000 to 1,336,000, a change of -9,979,000 (-88.2%).
- Net loss of 38,717,000 reduced equity.
- New share issuances of 23,850,000 increased equity.
- Other factors increased equity by 4,888,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-38.72 Million | -2897.98% |
| Share Issuances | €23.85 Million | +1785.18% |
| Other Changes | €4.89 Million | +365.87% |
| Total Change | €- | -88.19% |
Book Value vs Market Value Analysis
This analysis compares Landec Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 102.54x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.45x to 102.54x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-05-31 | €8.24 | €3.70 | x |
| 2018-05-31 | €9.12 | €3.70 | x |
| 2019-05-31 | €9.28 | €3.70 | x |
| 2020-05-31 | €7.91 | €3.70 | x |
| 2021-05-31 | €6.91 | €3.70 | x |
| 2022-05-31 | €3.66 | €3.70 | x |
| 2023-05-31 | €-0.06 | €3.70 | x |
| 2024-05-31 | €0.37 | €3.70 | x |
| 2025-05-31 | €0.04 | €3.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Landec Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2897.98%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -30.04%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 179.15x
- Recent ROE (-2897.98%) is below the historical average (-240.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 9.43% | 4.02% | 1.52x | 1.54x | €-1.16 Million |
| 2015 | 6.20% | 2.51% | 1.56x | 1.59x | €-8.30 Million |
| 2016 | -5.52% | -2.15% | 1.58x | 1.63x | €-32.71 Million |
| 2017 | 4.67% | 1.99% | 1.48x | 1.58x | €-12.07 Million |
| 2018 | 9.83% | 4.74% | 1.30x | 1.60x | €-427.20K |
| 2019 | 0.15% | 0.07% | 1.07x | 1.92x | €-26.60 Million |
| 2020 | -16.53% | -6.47% | 1.09x | 2.34x | €-61.30 Million |
| 2021 | -16.11% | -6.00% | 1.08x | 2.48x | €-52.94 Million |
| 2022 | -89.92% | -52.34% | 0.63x | 2.73x | €-108.05 Million |
| 2023 | 0.00% | -98.96% | 0.40x | 0.00x | €-102.01 Million |
| 2024 | 106.17% | 9.37% | 0.51x | 22.44x | €10.88 Million |
| 2025 | -2897.98% | -30.04% | 0.54x | 179.15x | €-38.85 Million |
Industry Comparison
This section compares Landec Corporation's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Landec Corporation (LDE) | €-10.54 Million | 9.43% | N/A | $75.13 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |